Quince Therapeutics, Inc. (NasdaqGS: QNCX)
Health Care · Biotechnology · US
$33.93
-0.32% today · -89.3% 1Y
Quince Therapeutics, Inc. (NasdaqGS: QNCX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $33.18M and employs 38 people.
Over the last twelve months the share price has lost 89.3%, trading between 15.10 and 909.98.
Tweenvest scores Quince Therapeutics, Inc. across four factors: quality 27/100. Its strongest factor is quality.
QNCX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $33.18M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -51.81
- Dividend yield
- —
- Beta (5Y)
- 1.26
- 52-week high
- $909.98
- 52-week low
- $15.10
- Avg volume (3M)
- —
- Shares outstanding
- 977.96K
- Employees
- 38
- Next earnings
- —
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
- ISIN
- US22053A3059
- Founded
- 2012
- Listed since
- May 9, 2019
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.97 | +0.58% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $142.92 | -1.48% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.